viewSilence Therapeutics PLC

Silence Therapeutics makes clinical trial application for lead drug

Chief executive, Dr David Horn Solomon, said the submission was a “very positive step forward” as it continued preparations for its return to the clinic

The company is gearing up to start work in the clinic sometime in the third quarter

Silence Therapeutics PLC (LON:SLN) has made a clinical trial application for its lead candidate, which is being developed to treat iron overload disorders.

SLN124 already has orphan drug designation in Europe, which could shorten its timeline to market while providing the approved product with additional exclusivity.

“Promising candidate medicine”

Silence describes SLN124 as a “promising candidate medicine” for patients with iron overload disorders such as ß -Thalassemia, Myelodysplastic Syndrome and Hereditary Hemochromatosis.

A phase Ib, first-in-human trial is scheduled to start in the third quarter.

Chief executive, Dr David Horn Solomon, said the submission was a “very positive step forward” as Silence continued preparations for its return to the clinic.

“With robust data generated in several preclinical disease models, favourable safety profile and patient-friendly administration, we believe that SLN124 is well positioned against the current standard of care and other medicines in development for the treatment of iron overload disorders.”

Quick facts: Silence Therapeutics PLC

Price: 505 GBX

Market: AIM
Market Cap: £395.77 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...



Silence Therapeutics 'in a hot space with few competitors'

Silence Therapeutics' (LON:SLN) executive chair Annalisa Jenkins sat down with Proactive's Andrew Scott to discuss her strategy for taking the drug developer forward and the 'exciting opportunities' in the RNAi space. On what attracted Jenkins to join Silence, she says: ''The opportunity...

on 12/6/18


Additional Listing

2 weeks, 5 days ago

Additional Listing

3 weeks, 3 days ago

Holding(s) in Company

on 14/11/19

Additional Listing

on 31/10/19

Additional Listing

on 25/10/19

Holding(s) in Company

on 14/10/19

Holdings in Company

on 7/10/19

2 min read